<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109914</url>
  </required_header>
  <id_info>
    <org_study_id>MICH P10.011</org_study_id>
    <nct_id>NCT01109914</nct_id>
  </id_info>
  <brief_title>Mucosal Response in Immunocompromised Host</brief_title>
  <acronym>MICH</acronym>
  <official_title>Immune Response After Inactivated Oral Cholera Vaccine (Dukoral) in Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crucell B.V., Leiden, the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to verify whether vaccination with Dukoral® (SBL Vaccines) induces&#xD;
      an immune response in renal transplant recipients on prednisolone in combination with either&#xD;
      a calcineurin inhibitor CNI) or mycophenolate mofetil (MMF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      LT-ETEC is the most common cause of travelers' diarrhoea. Dukoral® (SBL Vaccines) reduces the&#xD;
      severity and duration of LT-ETEC induced diarrhea. Dehydration due to diarrhea poses a risk&#xD;
      to the health of renal transplant recipients. Therefore Dukoral may benefit this group of&#xD;
      travelers.&#xD;
&#xD;
      AIM OF THIS STUDY:&#xD;
&#xD;
      Primary objective: To verify whether vaccination with Dukoral® (SBL Vaccines) induces an&#xD;
      immune response in renal transplant recipients on prednisolone in combination with either a&#xD;
      calcineurin inhibitor (cyclosporine or tacrolimus) or mycophenolate mofetil.&#xD;
&#xD;
      Secondary objective: To evaluate to what extent, the immune response differs, depending on&#xD;
      the use of different classes of immunosuppressive drugs (CNI or MMF).&#xD;
&#xD;
      STUDY DESIGN:&#xD;
&#xD;
      Single center interventional study.&#xD;
&#xD;
      Population: The population base of the study consists of adult renal transplant recipients&#xD;
      who received their transplant at our medical center. The control population consists of the&#xD;
      healthy partners and siblings of the renal transplant recipients. We intend to include 10&#xD;
      healthy volunteers and 60 renal transplant recipients (20 on prednisolone and a CNI and 20 on&#xD;
      prednisolone and MMF).&#xD;
&#xD;
      Intervention: Dukoral® (SBL Vaccines) will be administered orally at baseline (day 0) and at&#xD;
      day 14.&#xD;
&#xD;
      Laboratory analysis: Serum CTB antibody (ELISA), Vibriocidal assay. The analysis is performed&#xD;
      at Crucell.&#xD;
&#xD;
      Statistical analysis: No formal sample-size calculation was performed. The crude outcome&#xD;
      estimates will be adjusted for variables that may influence the outcome (age, time after&#xD;
      transplantation, past treatment for transplant rejection, current renal function, cumulative&#xD;
      prednisolone dose, serum concentration (i.e. area under the curve) of CNI and MMF.&#xD;
&#xD;
      Note: the study intended to also recruit a study arm consisting of patients on a mTORi.&#xD;
      Recruitment for this study arm was unsuccesful due to the scarcity of elligible patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage seroconversion among all renal transplant recipients.</measure>
    <time_frame>day 20-22</time_frame>
    <description>≥3-fold rise in serum anti-CTB antibodies or ≥4-fold rise in serum vibriocidal antibodies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Group differences in geometric mean antibody titers after vaccination</measure>
    <time_frame>day 20-22</time_frame>
    <description>post-vaccination anti-rCTB titers, measured by Enzyme Immuno Assay (EIA); post-vaccination serum vibriocidal antibodies, measured in vibriocidal assay.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Immunity</condition>
  <arm_group>
    <arm_group_label>Renal transplant recipients (MMF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal transplant recipients using prednisolone and mycophenolate mofetil (MMF) but no other immunosuppressive drug.&#xD;
Intervention: vaccination with Dukoral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal transplant recipients (CNI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal transplant recipients using prednisolone and a calcineurin inhibitor (cyclosporine or tacrolimus) but no other immunosuppressive drug.&#xD;
Intervention: vaccination with Dukoral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers (partners, brothers or sisters of the renal transplant recipients).&#xD;
Intervention: vaccination with Dukoral</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dukoral</intervention_name>
    <description>Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:&#xD;
Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria*&#xD;
Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria*&#xD;
Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria*&#xD;
Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria*&#xD;
Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Renal transplant recipients (CNI)</arm_group_label>
    <arm_group_label>Renal transplant recipients (MMF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        HEALTHY VOLUNTEERS&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Above 18 years of age&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of an auto-immune disease (SLE, ANCA associated vasculitis, Goodpasture,&#xD;
             Henoch Schonlein, cryoglobulinemia, secondary vasculitis, polyarteritis nodosa and&#xD;
             immunodeficiency disorders like IgA deficiency)&#xD;
&#xD;
          -  Chronic infection&#xD;
&#xD;
          -  Past vaccination with Dukoral or another cholera or ETEC vaccine&#xD;
&#xD;
          -  History of infection with Vibrio cholerae&#xD;
&#xD;
          -  Episode of diarrhoea in the 6 months prior to inclusion&#xD;
&#xD;
          -  Allergy to vaccine-specific components&#xD;
&#xD;
          -  History of a severe allergic reaction to any vaccine&#xD;
&#xD;
          -  Treatment with blood products in the 3 months prior to inclusion&#xD;
&#xD;
          -  Current pregnancy or breastfeeding&#xD;
&#xD;
          -  Premenopausal women not willing to use contraceptives during the first 60 days after&#xD;
             vaccination&#xD;
&#xD;
          -  Use of any immunosuppressive drug&#xD;
&#xD;
        RENAL TRANSPLANT RECIPIENTS&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Above 18 years of age&#xD;
&#xD;
          -  Creatinin clearance ≥ 40 ml/min measured in the 6 months prior to inclusion&#xD;
&#xD;
          -  Stable renal function for 1 year prior to inclusion&#xD;
&#xD;
          -  Stable immunosuppressive regimen of a CNI, MMF or mTORi combined with prednisolone for&#xD;
             at least 3 months prior to inclusion&#xD;
&#xD;
          -  Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of an auto-immune disease (SLE, ANCA associated vasculitis, Goodpasture,&#xD;
             Henoch Schonlein, cryoglobulinemia, secondary vasculitis, polyarteritis nodosa and&#xD;
             immunodeficiency disorders like IgA deficiency)&#xD;
&#xD;
          -  Chronic infection&#xD;
&#xD;
          -  Treatment for rejection of the transplant in the past 1 year prior to inclusion&#xD;
&#xD;
          -  Past vaccination with Dukoral or another cholera or ETEC vaccine&#xD;
&#xD;
          -  History of infection with Vibrio cholerae&#xD;
&#xD;
          -  Episode of diarrhoea in the 6 months prior to inclusion&#xD;
&#xD;
          -  Allergy to vaccine-specific components&#xD;
&#xD;
          -  History of a severe allergic reaction to any vaccine&#xD;
&#xD;
          -  Treatment with blood products in the 3 months prior to inclusion&#xD;
&#xD;
          -  Current pregnancy or breastfeeding&#xD;
&#xD;
          -  Premenopausal women not willing to use contraceptives during the first 60 days after&#xD;
             vaccination&#xD;
&#xD;
          -  Use of an immunosuppressive drug other than CNI, MMF, mTORi or prednisolone at the the&#xD;
             time of inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo G Visser, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darius Soonawala, MD</last_name>
    <role>Study Director</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>O W Bredewold, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J W de Fijter, Prof PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marjolein AC Uijlings</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emile FF Jonker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leiden Univeristy Medical Centre</name>
      <address>
        <city>Leiden</city>
        <state>Zuid-Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Darius Soonawala</investigator_full_name>
    <investigator_title>Drs</investigator_title>
  </responsible_party>
  <keyword>Renal transplantation</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>ETEC</keyword>
  <keyword>Dukoral</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Immunity, Humoral</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

